Antithrombin Market Size, Share & Trends Analysis Report By Application (Therapeutics, Diagnostics), By Source (Human, Recombinant Goat Milk), By Type, By Region, And Segment Forecasts, 2025 - 2033
Description
Antithrombin Market Summary
The global antithrombin market size was estimated at USD 658.4 million in 2024 and is projected to reach USD 997.2 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033. The rising prevalence of coagulation disorders such as deep vein thrombosis, pulmonary embolism, and hereditary antithrombin deficiency primarily drives the antithrombin market.
Increasing surgical procedures, trauma cases, and complications during pregnancy that elevate thrombosis risk are also contributing to higher demand for antithrombin therapy. The antithrombin industry is driven by the steady rise of thromboembolic and coagulation disorders, growing awareness of hereditary antithrombin deficiency, and the importance of early anticoagulant therapy. In the U.S, 900,000 people are affected by venous thromboembolism (VTE) each year, with individuals at particularly high risk during or just after hospitalization, cancer treatment, or pregnancy. An estimated 60,000 to 100,000 Americans die annually from VTE, while many others experience long-term complications, thus highlighting the critical need for effective prevention and management.
Increasing surgical procedures, trauma incidents, and pregnancy-related complications have further amplified the demand for antithrombin therapy. Treatment options worldwide include plasma-derived and recombinant formulations, with recombinant products gaining wider acceptance due to higher safety, purity, and reduced infection risks. The expansion of their use in critical care, cardiac surgeries, and obstetric cases, supported by advancements in biotechnology and favorable regulatory approvals, continues to propel the global antithrombin market forward.
Global Antithrombin Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antithrombin market report based on application, source, type, and region:
The global antithrombin market size was estimated at USD 658.4 million in 2024 and is projected to reach USD 997.2 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033. The rising prevalence of coagulation disorders such as deep vein thrombosis, pulmonary embolism, and hereditary antithrombin deficiency primarily drives the antithrombin market.
Increasing surgical procedures, trauma cases, and complications during pregnancy that elevate thrombosis risk are also contributing to higher demand for antithrombin therapy. The antithrombin industry is driven by the steady rise of thromboembolic and coagulation disorders, growing awareness of hereditary antithrombin deficiency, and the importance of early anticoagulant therapy. In the U.S, 900,000 people are affected by venous thromboembolism (VTE) each year, with individuals at particularly high risk during or just after hospitalization, cancer treatment, or pregnancy. An estimated 60,000 to 100,000 Americans die annually from VTE, while many others experience long-term complications, thus highlighting the critical need for effective prevention and management.
Increasing surgical procedures, trauma incidents, and pregnancy-related complications have further amplified the demand for antithrombin therapy. Treatment options worldwide include plasma-derived and recombinant formulations, with recombinant products gaining wider acceptance due to higher safety, purity, and reduced infection risks. The expansion of their use in critical care, cardiac surgeries, and obstetric cases, supported by advancements in biotechnology and favorable regulatory approvals, continues to propel the global antithrombin market forward.
Global Antithrombin Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antithrombin market report based on application, source, type, and region:
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Therapeutics
- Diagnostics
- Research
- Other
- Source Outlook (Revenue, USD Million, 2021 - 2033)
- Human
- Recombinant Goat Milk
- Others
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Anticoagulant
- Antiplatelet
- Thrombolytic Drugs
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Application
- 1.2.2. Source
- 1.2.3. Type
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.8. List of Secondary Source
- 1.9. List of Primary Source
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Application outlook
- 2.2.2. Source outlook
- 2.2.3. Type outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Antithrombin Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. Antithrombin Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- Chapter 4. Antithrombin Market: Application Estimates & Trend Analysis
- 4.1. Application Segment Dashboard
- 4.2. Antithrombin Market: Application Movement Analysis
- 4.3. Global Antithrombin Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 4.3.1. Therapeutics
- 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.2. Diagnostics
- 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.3. Research
- 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 4.3.4. Other
- 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 5. Antithrombin Market: Source Estimates & Trend Analysis
- 5.1. Source Segment Dashboard
- 5.2. Antithrombin Market: Source Movement Analysis
- 5.3. Global Antithrombin Market Size & Trend Analysis, by Source, 2021 to 2033 (USD Million)
- 5.3.1. Human
- 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.2. Recombinant Goat Milk
- 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 5.3.3. Others
- 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 6. Antithrombin Market: Type Estimates & Trend Analysis
- 6.1. Type Segment Dashboard
- 6.2. Antithrombin Market: Type Movement Analysis
- 6.3. Global Antithrombin Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
- 6.3.1. Anticoagulant
- 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.2. Antiplatelet
- 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 6.3.3. Thrombolytic Drugs
- 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 7. Antithrombin Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Dashboard
- 7.2. Regional Market Share Analysis, 2024 & 2030
- 7.3. Antithrombin Market by Region: Key Takeaways
- 7.4. North America
- 7.4.1. U.S.
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.2. Canada
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4.3. Mexico
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.6. Sweden
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework/ reimbursement structure
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5.8. Norway
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework/ reimbursement structure
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. China
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.2. India
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.3. Japan
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Regulatory framework/ reimbursement structure
- 7.6.3.3. Competitive scenario
- 7.6.3.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.4. Australia
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Regulatory framework/ reimbursement structure
- 7.6.4.3. Competitive scenario
- 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key country dynamics
- 7.6.5.2. Regulatory framework/ reimbursement structure
- 7.6.5.3. Competitive scenario
- 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6.6. Thailand
- 7.6.6.1. Key country dynamics
- 7.6.6.2. Regulatory framework/ reimbursement structure
- 7.6.6.3. Competitive scenario
- 7.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Brazil
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7.2. Argentina
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8. MEA
- 7.8.1. South Africa
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Regulatory framework/ reimbursement structure
- 7.8.1.3. Competitive scenario
- 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.2. Saudi Arabia
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Regulatory framework/ reimbursement structure
- 7.8.2.3. Competitive scenario
- 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.3. UAE
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Regulatory framework/ reimbursement structure
- 7.8.3.3. Competitive scenario
- 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 7.8.4. Kuwait
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Regulatory framework/ reimbursement structure
- 7.8.4.3. Competitive scenario
- 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. Key company heat map analysis, 2024
- 8.4. Company Profiles
- 8.4.1. CSL
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Grifols, S.A.
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Takeda Pharmaceutical Company Limited.
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. Octapharma AG
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. LFB
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. ENDPOINT HEALTH, INC.
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. Siemens Healthineers AG
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Thermo Fisher Scientific Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Medix Biochemica
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
